Congratulations to Vertex for their UK approval for CASGEVY™, a CRISPR/Cas9 gene-edited therapy, for the treatment of sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT).
We are proud to have contributed to Vertex’s cold chain with full transport validation support, including transport simulation testing using Modality Solutions’ Advantage Transport Simulation Laboratory™.
Today, four leading life science companies—Suttons Creek, Modality Solutions, CLINTREX, and ToxStrategies—announce their unification...
read Details
Modality Solutions is proud to announce the launch of our new Greenwood Lab—a state-of-the-art...
read Details
Congratulations to Melinta Therapeutics for their FDA Approval of REZZAYO™ for the Treatment of...
read Details
